Mobile Team Leader

Exeter, England, gb

Centre for Human Genetics, Building for Genomic Medicine, Old Road Campus, Roosevelt Drive, Headington, Oxford, OX3 7BN Applications are invited for a Research Assistant in Functional Genomics of Sepsis to join Professor Julian Knight’s research group, an established team with a track record of innovation and high impact research in functional genomics, sepsis and susceptibility to multi-factorial disease. This is an exciting new position funded through a collaboration with the Danaher corporation and its subsidiary Cepheid. This research is part of the Beacon programme ‘Development and prospective evaluation of point-of-need test for sepsis subtyping based on gene expression using the Cepheid GeneXpert platform’. The programme seeks to advance precision medicine for patients with sepsis by developing a point-of-care test to stratify patients based on their immune response profiles. We aim to use an integrated approach which leverages the host transcriptome, immune profiling, and electronic health records, in combination with the GeneXpert system for mRNA quantification. Our goal is to deliver a precision medicine approach for managing patients with severe infections. The work is highly collaborative with clinical teams, company partners, and expert investigators across the UK, the US, and Sweden. You will facilitate exciting new collaborative links with Danaher, which may involve travel to Sweden (Cepheid) and the United States (Danaher). You will have a degree in biology, genetics, immunology, biochemistry, molecular biology or related field and relevant research experience of patient blood or tissue sample processing in the laboratory and management of sample collections. You will be motivated by a stimulating and ambitious research environment with a desire to deliver high quality cutting-edge science and work in a laboratory offering the opportunity for career development and acquiring new expertise. This position is offered full time on a fixed term contract until 30 September 2027 and is funded by the Danaher Corporation. The anticipated start date is 1 September 2025.